22 May 2013
Keywords: serono, clarity, trial, starts, enrolling, swiss, biotechnology
Article | 15 May 2006
Swiss biotechnology group Serono has started recruitement for the Phase III USA-based CLAdRIbine Tablets in Treating MS OrallY Study (CLARITY),
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 May 2006
© 2013 thepharmaletter.com